109 related articles for article (PubMed ID: 8858063)
1. Advances in ALS workshop summary: Research and future goals.
Brooke MH; Strong MJ
Neurology; 1996 Oct; 47(4 Suppl 2):S108-12. PubMed ID: 8858063
[No Abstract] [Full Text] [Related]
2. Excitotoxins and amyotrophic lateral sclerosis.
Munsat TL; Hollander D
Therapie; 1990; 45(3):277-9. PubMed ID: 2194313
[TBL] [Abstract][Full Text] [Related]
3. Oxidative and excitotoxic insults exert differential effects on spinal motoneurons and astrocytic glutamate transporters: Implications for the role of astrogliosis in amyotrophic lateral sclerosis.
Zagami CJ; Beart PM; Wallis N; Nagley P; O'Shea RD
Glia; 2009 Jan; 57(2):119-35. PubMed ID: 18661557
[TBL] [Abstract][Full Text] [Related]
4. Aberrant control of motoneuronal excitability in amyotrophic lateral sclerosis: excitatory glutamate/D-serine vs. inhibitory glycine/gamma-aminobutanoic acid (GABA).
Sasabe J; Aiso S
Chem Biodivers; 2010 Jun; 7(6):1479-90. PubMed ID: 20564566
[TBL] [Abstract][Full Text] [Related]
5. A review of experimental research on herbal compounds in amyotrophic lateral sclerosis.
Zhang X; Hong YL; Xu DS; Feng Y; Zhao LJ; Ruan KF; Yang XJ
Phytother Res; 2014 Jan; 28(1):9-21. PubMed ID: 23519768
[TBL] [Abstract][Full Text] [Related]
6. Excitotoxicity in ALS.
Leigh PN; Meldrum BS
Neurology; 1996 Dec; 47(6 Suppl 4):S221-7. PubMed ID: 8959993
[No Abstract] [Full Text] [Related]
7. [Free amino acid contents in the spinal cord of amyotrophic lateral sclerosis].
Fujita K; Nagata Y; Honda M
Rinsho Shinkeigaku; 1993 Sep; 33(9):985-7. PubMed ID: 7905368
[TBL] [Abstract][Full Text] [Related]
8. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis.
Rothstein JD; Tsai G; Kuncl RW; Clawson L; Cornblath DR; Drachman DB; Pestronk A; Stauch BL; Coyle JT
Ann Neurol; 1990 Jul; 28(1):18-25. PubMed ID: 2375630
[TBL] [Abstract][Full Text] [Related]
9. Brain glutamate deficiency in amyotrophic lateral sclerosis.
Perry TL; Hansen S; Jones K
Neurology; 1987 Dec; 37(12):1845-8. PubMed ID: 2891083
[TBL] [Abstract][Full Text] [Related]
10. Zinc pre-treatment enhances NMDAR-mediated excitotoxicity in cultured cortical neurons from SOD1(G93A) mouse, a model of amyotrophic lateral sclerosis.
Nutini M; Frazzini V; Marini C; Spalloni A; Sensi SL; Longone P
Neuropharmacology; 2011 Jun; 60(7-8):1200-8. PubMed ID: 21056589
[TBL] [Abstract][Full Text] [Related]
11. [Neurotoxic activity of serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients against some enzymes of glutamate metabolism].
Niebroj-Dobosz I; Janik P; Mickielewicz A; Jamrozik Z; Kwieciński H
Neurol Neurochir Pol; 2001; 35(1 Suppl):81-9. PubMed ID: 11732283
[TBL] [Abstract][Full Text] [Related]
12. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis.
Rothstein JD
Adv Neurol; 1995; 68():7-20; discussion 21-7. PubMed ID: 8787245
[TBL] [Abstract][Full Text] [Related]
13. Animal models of BMAA neurotoxicity: a critical review.
Karamyan VT; Speth RC
Life Sci; 2008 Jan; 82(5-6):233-46. PubMed ID: 18191417
[TBL] [Abstract][Full Text] [Related]
14. Spatial clustering of amyotrophic lateral sclerosis and the potential role of BMAA.
Caller TA; Field NC; Chipman JW; Shi X; Harris BT; Stommel EW
Amyotroph Lateral Scler; 2012 Jan; 13(1):25-32. PubMed ID: 22214351
[TBL] [Abstract][Full Text] [Related]
15. Neurofilaments, free radicals, excitotoxins, and amyotrophic lateral sclerosis.
al-Chalabi A; Powell JF; Leigh PN
Muscle Nerve; 1995 May; 18(5):540-5. PubMed ID: 7739643
[TBL] [Abstract][Full Text] [Related]
16. Decrease in glial glutamate transporter variants and excitatory amino acid receptor down-regulation in a murine model of ALS-PDC.
Wilson JM; Khabazian I; Pow DV; Craig UK; Shaw CA
Neuromolecular Med; 2003; 3(2):105-18. PubMed ID: 12728193
[TBL] [Abstract][Full Text] [Related]
17. Excitotoxic neuronal cell death in amyotrophic lateral sclerosis.
Appel SH
Trends Neurosci; 1993 Jan; 16(1):3-5. PubMed ID: 7679235
[No Abstract] [Full Text] [Related]
18. Sera from amyotrophic lateral sclerosis patients induce the non-canonical activation of NMDA receptors "in vitro".
Texidó L; Hernández S; Martín-Satué M; Povedano M; Casanovas A; Esquerda J; Marsal J; Solsona C
Neurochem Int; 2011 Nov; 59(6):954-64. PubMed ID: 21782871
[TBL] [Abstract][Full Text] [Related]
19. Editor's Highlight: Embryonic Exposure to the Environmental Neurotoxin BMAA Negatively Impacts Early Neuronal Development and Progression of Neurodegeneration in the Sod1-G93R Zebrafish Model of Amyotrophic Lateral Sclerosis.
Powers S; Kwok S; Lovejoy E; Lavin T; Sher RB
Toxicol Sci; 2017 May; 157(1):129-140. PubMed ID: 28123103
[TBL] [Abstract][Full Text] [Related]
20. Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis.
Bradley WG
Amyotroph Lateral Scler; 2009; 10 Suppl 2():118-23. PubMed ID: 19929743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
